Table 1.
Characteristics of studies included in the meta-analysis.
| Study | Country | TAM detection assay | TAM marker | Patient characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor status | Patients, n | Age, yearmean ± SD (range) | Gender, n (male/female) | Tumor status, n (%) | Fuhrman grade, n (%) | Tumor necrosis, n (%) | Tumor grade, n (%) | Median follow-up, month (range) | ||||
| Komohara et al. (19) | Japan | IHC | CD163 | Primary ccRCC | 66 | NA | 46/20 | T1, 30 (45.5); T2,3, 36 (54.5) |
G1 10 (15.2), G2 32 (48.5), G3,4 24 (36.3) | NA | G1,2 42 (63.6); G3,4 24 (36.4) |
NA |
| Dannenmann et al. (25) | Switzerland | qPCR | CD68, CD163 | Primary ccRCC with no prior treatment | 54 | 66.3 ± 7.2 (40–86) | NA | T1, 21 (38.9); T2, 4 (7.4); T3, 28 (51.9); T4, 1 (1.8) | NA | NA | NA | 80.9 ± 64.2‡ (NA) |
| Xu et al. (23) | China | IHC | CD68, CD11c, CD206 | Primary ccRCC with no prior treatment | 185 | 60.7 ± 12.4 (30–84) | 70/115 | T1, 119 (64.3); T2, 33 (17.9); T3, 33 (17.9) |
G1,2, 74 (40.0%) G3,4, 111 (60.0%) |
Absent 106(57.3), present 79(42.7) | NA | 70 (10–120) |
| Komohara et al. (20) | Japan | IHC | CD204 | Primary ccRCC undergone curative surgery | 91 | NA | 59/32 | T1, 42 (46.2); T2–4, 49 (53.8); |
G1,2 74 (81.3), G3,4 17 (18.7) | NA | NA | NA |
| Cros et al. (26) | France | IHC | CD68, CD163 | Primary ccRCC | 257 | 61.3 ± 11.7 (NA) | 171/86 | T1 143 (55.6), T2 26 (10.1), T3 85 (33.1), T4 3 (1.2) | NA | NA | G1,2 156 (60.7), G3,4101 (39.3) | 72 (22.8–112.8) |
| Nakanishi et al. (21) | Japan | IHC | CD68 | Primary ccRCC with no prior treatment | 179 | NA | NA | NA | NA | NA | NA | 39 (19–62)§ |
| Ma, 2017 | Japan | IHC | CD163 | Primary ccRCC undergone curative surgery | 103 | NA | 54/49 | T1, 66 (64.1); T2–4, 37 (35.9) | G1,2 81 (78.6), G3,4 22 (21.4) | NA | NA | NA |
| Wang et al. (24) cohort 1 | China | IHC | CD68, CD163 | Primary ccRCC | 110 | NA | 87/23 | NA | NA | NA | G1,2 68 (61.8), G3,4 42 (38.2) | NA |
| Wang et al. (24) cohort 2 | China | IHC | CD68, CD163 | Primary ccRCC | 143 | NA | 85/58 | NA | NA | NA | G1,2 107 (74.8), G3,4 36 (25.2) | NA |
TAM, tumor-associated macrophage; IHC, immunohistochemistry; ccRCC, clear cell renal cell carcinoma, qPCR, quantitative polymerase chain reaction; NA, not available.
‡Mean ± Standard deviation.
§Median (Interquartile range).